Literature DB >> 21169387

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Henry Krum1, Barry Massie, William T Abraham, Kenneth Dickstein, Lars Kober, John J V McMurray, Ashkay Desai, Claudio Gimpelewicz, Albert Kandra, Bernard Reimund, Henning Rattunde, Juergen Armbrecht.   

Abstract

AIMS: The renin-angiotensin-aldosterone system (RAAS) represents a key therapeutic target in heart failure (HF) management. However, conventional agents that block this system induce a reflex increase in plasma renin activity (PRA), which may lead to RAAS 'escape'. Direct renin inhibitors (DRIs) have been developed that decrease PRA and thus may provide a greater RAAS blockade. Aliskiren is the first orally active DRI. Plasma levels of B-type natriuretic peptide (BNP) have been observed to be reduced with aliskiren compared with placebo. The aim of the Aliskiren Trial of Minimizing OutcomeS for Patients with HEart failuRE (ATMOSPHERE) study is to evaluate the effect of both aliskiren and enalapril monotherapy and aliskiren/enalapril combination therapy on cardiovascular death and HF hospitalization in patients with chronic systolic HF, NYHA functional class II-IV symptoms, and elevated plasma levels of BNP. Methods Patients tolerant to at least 10 mg or equivalent of enalapril will undergo an open-label run-in period where they receive enalapril then aliskiren. Approximately 7000 patients tolerating this run-in period will then be randomized 1:1:1 to aliskiren monotherapy, enalapril monotherapy, or the combination. The primary endpoints of ATMOSPHERE are (i) whether the aliskiren/enalapril combination is superior to enalapril monotherapy in delaying time to first occurrence of cardiovascular death or HF hospitalization and (ii) whether aliskiren monotherapy is superior or at least non-inferior to enalapril monotherapy on this endpoint. Perspective The ATMOSPHERE study will definitively determine the role of a DRI strategy additional to or as an alternative to conventional RAAS blockade in patients with chronic systolic HF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169387     DOI: 10.1093/eurjhf/hfq212

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  34 in total

Review 1.  Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

Authors:  Massimo Volpe; Roberto Pontremoli; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

2.  Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.

Authors:  Selçuk Sen; Soner Sabırlı; Tolga Ozyiğit; Yağız Uresin
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

3.  Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Authors:  Aldo P Maggioni; Stephen J Greene; Gregg C Fonarow; Michael Böhm; Faiez Zannad; Scott D Solomon; Eldrin F Lewis; Fabio Baschiera; Tsushung A Hua; Claudio R Gimpelewicz; Anastasia Lesogor; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2013-09-02       Impact factor: 29.983

Review 4.  Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.

Authors:  Archyut Valluri; Allan D Struthers; Chim C Lang
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 5.  Modulation of the renin-angiotensin-aldosterone system in heart failure.

Authors:  J George; A D Struthers; C C Lang
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

6.  Renin-angiotensin system blockade: time for a reappraisal?

Authors:  Luis M Ruilope
Journal:  Eur Heart J       Date:  2014-04-09       Impact factor: 29.983

Review 7.  Global cardiovascular protection in chronic kidney disease.

Authors:  Gema Ruiz-Hurtado; Pantelis Sarafidis; María S Fernández-Alfonso; Bernard Waeber; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

Review 8.  New Targets in the Drug Treatment of Heart Failure.

Authors:  James A Iwaz; Elizabeth Lee; Hermineh Aramin; Danilo Romero; Navaid Iqbal; Matt Kawahara; Fatima Khusro; Brian Knight; Minal V Patel; Sumita Sharma; Alan S Maisel
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

Review 9.  Targeting the renin-angiotensin-aldosterone system in heart failure.

Authors:  Chim C Lang; Allan D Struthers
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 10.  Heart failure in hypertension: prevention and treatment.

Authors:  Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos; Javed Butler
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.